•  
  •  
 

Abstract

In Indonesia, lung cancer is the leading cause of death related to cancer, according to Global Cancer Observatory. Chemotherapy is the most common treatment since it works systemically and can prevent cancer cells from spreading to other organs. Cytotoxicity of chemotherapy can also put patients at high risk of experiencing adverse effects. This study aimed to evaluate the congruity of chemotherapy use with treatment recommendations and the profile of adverse effects, not only acute but also delayed adverse drug reactions. This prospective observational study involved 41 adult patients with lung cancer who received chemotherapy. Data is collected through patients’ medical records, brief patient interviews, and analyzed descriptively. The majority of the patients received first-line chemotherapy (87.80%). Pemetrexed-cisplatin (39.02%) and pemetrexed-carboplatin (19.51%) are the most common first-line therapy, followed by docetaxel (12,20%) as the second-line chemotherapy commonly used by patients. The chemotherapy regimens used in patients were 100% appropriate based on treatment guidelines. 61.11% and 60% of patients experience adverse effects with the first and second line of chemotherapy, respectively. Anemia (63,89%) was the most common delayed adverse effect in the first-line chemotherapy and hair loss (60%) was the most common one in the second-line chemotherapy. The platinum-based chemotherapy is a standard treatment for lung cancer, but its tolerability limits its uses. These findings showed chemotherapy-related adverse effects that need to be considered in choosing the best choice of therapy to optimize the treatment. Therefore, prophylaxis therapy to manage chemotherapy-related adverse effects may be considered in patients with chemotherapy.

References

Abe, S. K., Ihira, H., Minami, T., Imatoh, T., Inoue, Y., Tsutsumimoto, K., . . . Doi, T. (2023). Prevalence of family history of cancer in the NC-CCAPH consortium of Japan. Scientific Reports, 13(1), 3128. 

Burke, M., & Rashdan, S. (2021). Management of immune-related adverse events in patients with non-small cell lung cancer. Frontiers in Oncology, 11, 720759. 

Cabanero, M., Sangha, R., Sheffield, B., Sukhai, M., Pakkal, M., Kamel-Reid, S., . . . Butts, C. (2017). Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Current Oncology, 24(2), 111-119.

Chairudin, M. R., Marhana, I. A., & Erawati, D. (2019). Profil pasien kanker paru primer yang dirawat inap dan rawat jalan di rumah sakit umum daerah dr Soetomo Surabaya. Jurnal Respirasi, 5(3), 65-71. 

Cheng, Y. I., Gan, Y. C., Liu, D., Davies, M. P., Li, W. M., & Field, J. K. (2019). Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. BMC Cancer, 19, 1-17. 

Coté, M. L., Liu, M., Bonassi, S., Neri, M., Schwartz, A. G., Christiani, D. C., . . . Aben, K. K. (2012). Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. European Journal of Cancer, 48(13), 1957-1968. 

Dutkowska, A. E., & Antczak, A. (2016). Comorbidities in lung cancer. Advances in Respiratory Medicine, 84(3), 186-192. 

Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. (2024). Global cancer observatory: Cancer today. Retrieved from https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf 

Fernandes, S. S., & Saini, J. (2023). The impact of chemotherapy on quality of life in advanced-stage lung cancer patients. Indian Journal of Cancer, 60(3), 310-315. 

Goldschmidt, J., Monnette, A., Shi, P., Venkatasetty, D., Huang, H., & Chioda, M. (2021).Management of immune-related adverse events in patients with non-small cell lung cancer. Blood, 138, 1913. 

Gubens, M. A., & Wakelee, H. A. (2010). Docetaxel in the treatment of non-small cell lung carcinoma: An update and analysis. Lung Cancer: Targets and Therapy, 63-76. 

Hines, J. B., Bowar, B., Levine, E., Esposito, A., Garassino, M. C., & Bestvina, C. M. (2023). Targeted toxicities: Protocols for monitoring the adverse events of targeted therapies used in the treatment of non-small cell lung cancer. International Journal of Molecular Sciences, 24(11), 9429. 

Holme, J. A., Vondráček, J., Machala, M., Lagadic-Gossmann, D., Vogel, C. F., Le Ferrec, E., . . . Øvrevik, J. (2023). Lung cancer associated with combustion particles and fine particulate matter (PM2. 5)-The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor (AhR). Biochemical Pharmacology, 115801.

Jahn, F., Wörmann, B., Brandt, J., Freidank, A., Feyer, P., & Jordan, K. (2022). The prevention and treatment of nausea and vomiting during tumor therapy. Deutsches Ärzteblatt International, 119(21), 382. 

Ji, J., Sundquist, J., Sundquist, K., & Zheng, G. (2022). Familial risk associated with lung cancer as a second primary malignancy in first-degree relatives. BMC Cancer, 22(1), 1057. 

Kang, H. S., Shin, A. Y., Yeo, C. D., Park, C. K., Kim, J. S., Kim, J. W., . . . Kim, S. K. (2020). Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations. Journal of Thoracic Disease, 12(5), 1895. 

Kanwal, M., Ding, X.-J., & Cao, Y. (2017). Familial risk for lung cancer. Oncology Letters, 13(2), 535-542. 

Kobayashi, S., Terashima, T., Shiba, S., Yoshida, Y., Yamada, I., Iwadou, S., . . . Moriguchi, M. (2018). Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Science, 109(8), 2549-2557. 

Lewandowska, A., Rudzki, G., Lewandowski, T., Próchnicki, M., Rudzki, S., Laskowska, B., & Brudniak, J. (2020). Quality of life of cancer patients treated with chemotherapy. International Journal of Environmental Research and Public Health, 17(19), 6938. 

Lustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023). Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology, 20(8), 527-542. 

Michael, A., Ainsley, A., Joseph, A., & Jahan, N. (2020). First and second line chemotherapeutic regimens for non-small cell lung carcinomas-the efficacy of platinum, non-platinum and combination therapy: A literature review. Cureus, 12(11). 

Mustian, K. M., Darling, T. V., Janelsins, M. C., Jean-Pierre, P., Roscoe, J. A., & Morrow, G. R. (2008). Chemotherapy-Induced Nausea and Vomiting. US Oncol, 4(1), 19-23. doi:10.17925/ohr.2008.04.1.19 

Muthu, V., Mylliemngap, B., Prasad, K. T., Behera, D., & Singh, N. (2019). Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting. Lung India, 36(1), 32-37. 

Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., . . . Lantuejoul, S. (2022). The 2021 WHO classification of lung tumors: impact of advances since 2015. Journal of Thoracic Oncology, 17(3), 362-387. 

Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M., . . . De Marinis, F. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of Oncology, 33(5), 466-487. 

Pecci, F., Cantini, L., Metro, G., Ricciuti, B., Lamberti, G., Farooqi, A. A., & Berardi, R. (2022). Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs in Context, 11. 

Prapa, P., Papathanasiou, I. V., Bakalis, V., Malli, F., Papagiannis, D., & Fradelos, E. C. (2021). Quality of life and psychological distress of lung cancer patients undergoing chemotherapy. World Journal of Oncology, 12(2-3), 61. 

Rashdan, S., Minna, J. D., & Gerber, D. E. (2018). Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. The Lancet Respiratory Medicine, 6(6), 472-478. 

Saraswat, N., Chopra, A., Sood, A., Kamboj, P., & Kumar, S. (2019). A descriptive study to analyze chemotherapy-induced hair loss and its psychosocial impact in adults: Our experience from a tertiary care hospital. Indian Dermatology Online Journal, 10(4), 426-430. 

Semenenko, E., Banerjee, S., Olver, I., & Ashinze, P. (2023). Review of psychological interventions in patients with cancer. Supportive Care in Cancer, 31(4), 210. 

Souilah, S., Dermech, N., Benbetka, Y., Djami, N., Khennouf, K., Amrane, R., & Fissah, A. (2018). Anemia during lung cancer. European Respiratory Journal, 52(suppl 62): PA2822 

Steendam, C. M., Ernst, S. M., Badrising, S. K., Paats, M. S., Aerts, J. G., de Langen, A. J., & Dingemans, A.-M. C. (2023). Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study. Lung Cancer, 181, 107248. 

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.

Wang, Y., Zhang, R., Shen, Y., Su, L., Dong, B., & Hao, Q. (2019). Prediction of chemotherapy adverse reactions and mortality in older patients with primary lung cancer through frailty index based on routine laboratory data. Clinical Interventions in Aging, 1187-1197. 

Wolf, A., Oeffinger, K. C., Shih, T. Y.-C., Walter, L. C., Church, T. R., Fontham, E. T., . . . Perkins, R. B. (2023). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 

Yin, X., Chan, C. P. Y., Seow, A., Yau, W.-P., & Seow, W. J. (2021). Association between family history and lung cancer risk among Chinese women in Singapore. Scientific Reports, 11(1), 21862.

Yuliandra, Y., Nasif, H., Ermayanti, S., Sulistyowati, L., & Juwita, D. A. (2019). Hematologic toxicities of chemotherapy in lung cancer patients: A retrospective study in Dr. M. Djamil hospital Padang, Indonesia. Indonesian Journal of Clinical Pharmacy Volume, 8(2). 

Zhou, C., Li, M., Wang, Z., An, D., & Li, B. (2022). Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. International Immunopharmacology, 102, 108353.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.